Lv4
756 积分 2025-01-21 加入
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
4天前
已完结
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
7天前
已完结
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
7天前
已完结
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
15天前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
20天前
已完结
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study
20天前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
28天前
已完结
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial
1个月前
已完结
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
1个月前
已完结
皖公网安备34019202002308
